High calcium diet down-regulates kidney angiotensin-converting enzyme in experimental renal failure  by Pörsti, Ilkka et al.
Kidney International, Vol. 66 (2004), pp. 2155–2166
High calcium diet down-regulates kidney angiotensin-converting
enzyme in experimental renal failure
ILKKA PO¨RSTI, MENG FAN, PEETER KO¨O¨BI, PASI JOLMA, JARKKO KALLIOVALKAMA, TUIJA I. VEHMAS,
HEIKKI HELIN, HARRY HOLTHO¨FER, EERO MERVAALA, TUULIKKI NYMAN, and ILKKA TIKKANEN
Department of Internal Medicine, University of Tampere, Tampere, Finland; Department of Pharmacological Sciences, University of
Tampere, Tampere, Finland; Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland; Department of
Anaesthesia and Intensive Care, University of Tampere, Tampere, Finland; Department of Pathology, Tampere University Hospital,
Tampere, Finland; Programme of Molecular Medicine, Helsinki, Finland; Institute of Biomedicine, Biomedicum Helsinki, Helsinki,
Finland; and Minerva Institute for Medical Research, Helsinki, Finland
High calcium diet down-regulates kidney angiotensin-
converting enzyme in experimental renal failure.
Background. Calcium salts are used as phosphate binders in
renal failure, while high calcium diet also improves vasorelax-
ation and enhances natriuresis. The influences of calcium intake
on renal renin-angiotensin system (RAS) are largely unknown.
Methods. Four weeks after NTX, rats were put on 3.0% or
0.3% calcium diet for 8 weeks (12-week study). In additional ex-
periments, 15 weeks after NTX, rats were put on similar diets for
12 weeks (27-week study). Appropriate blood, urine, and kid-
ney samples were taken. Renal angiotensin-converting enzyme
(ACE) and angiotensin II receptors (AT1, AT2) were exam-
ined using autoradiography, ACE also using Western blotting,
and connective tissue growth factor (CTGF) using immunohis-
tochemistry.
Results. In the 12-week study, albuminuria increased 5-fold in
NTX rats, but only 2-fold in calcium NTX rats on 3.0% calcium.
In the 27-week study, high calcium intake decreased blood pres-
sure, retarded progression of renal failure, reduced glomeru-
losclerosis, interstitial damage, and aortic calcifications, and
improved survival from 50% to 92% in NTX rats. In both ex-
periments plasma parathyroid hormone and phosphate were
elevated after NTX, and suppressed by high calcium diet, while
kidney ACE was down-regulated by 40% or more after in-
creased calcium intake. In the 27-week study renal CTGF was
decreased and cortical AT1 receptor density reduced after high
calcium diet.
Conclusion. High calcium diet down-regulated kidney ACE,
reduced albuminuria and blood pressure, and favorably influ-
enced kidney morphology in experimental renal failure. These
findings suggest a link between calcium metabolism and kidney
ACE expression, which may play a role in the progression of
renal damage.
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Chronic renal failure (CRF) is associated with in-
creased cardiovascular morbidity and mortality, the
underlying causes of which include anemia, acidosis, hy-
pertension, volume overload, and accumulation of ure-
mic toxins [1, 2]. Changes in calcium-phosphate balance,
especially hyperphosphatemia, are also closely associated
with the decline of kidney function, ectopic calcification,
and reduced survival in renal patients. Disturbed calcium-
phosphorus balance is a major cause for cardiovascular
complications during impaired kidney function [1, 2].
Phosphate retention, hypocalcemia, and reduced vita-
min D levels lead to the development of secondary hyper-
parathyroidism in CRF [3]. Elevated plasma phosphate
and parathyroid hormone (PTH) can be suppressed by di-
etary phosphate restriction, but oral phosphate binders,
most commonly calcium salts, are usually required to
manage hyperphosphatemia and hyperparathyroidism
during chronic kidney disease [3].
In experimental hypertension high calcium diet has
consistently reduced blood pressure [4, 5]. High calcium
intake has also decreased plasma renin activity (PRA)
[6], reduced angiotensin II (Ang II) binding sites in api-
cal brush-border membrane of renal cortex [7], and in-
creased sodium excretion in spontaneously hypertensive
rats [8, 9]. The mechanisms of the increased natriuresis
by high calcium intake are not well established, but in
addition to suppression of plasma renin, stimulation of
calcium-sensing receptors in nephrons may play a role,
with the subsequent reduction in sodium reabsorption
[10]. Recently, high dietary calcium intake was reported
to normalize the disturbances in calcium homeostasis
due to vitamin D deficiency by regulating the expression
of renal calcium transport protein genes, but increased
calcium intake also influenced the expression of several
other genes that were not playing a role in calcium han-
dling [11].
The renin-angiotensin system (RAS) is a major regu-
lator of sodium metabolism, renal function, arterial tone,
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and blood pressure. Expression of human angiotensino-
gen in the kidneys of mice results in hypertension in the
absence of changes in systemic Ang II [12]. Local in-
trarenal RAS is considered to play an important role in
the progression of kidney diseases [13].
The influences of increased calcium intake on blood
pressure, vascular tone, and natriuresis in experimental
animals resemble those effects that are obtained by in-
hibition of the actions of RAS. However, limited data
is available about the effects of high calcium diet on
RAS and progression of renal damage. In this study,
we tested the hypothesis whether increased calcium in-
take could beneficially influence the renal components of
RAS in rats subjected to NTX. The present results show
that, in addition to controlling plasma phosphate and
PTH, increased calcium intake down-regulates kidney
angiotensin-converting enzyme (ACE) in experimental
CRF.
METHODS
Animals and experimental design
Male Sprague-Dawley rats were used (N = 76) with
free access to water and food pellets (Lactamin R34;
AnalyCen, Lindko¨ping, Sweden). The chow contained
0.9% calcium, 0.8% phosphorus, 0.27% sodium, 0.2%
magnesium, 0.6% potassium, 12,550 kJ/kg energy, 16.5%
protein, 4.0% fat, 58% nitrogen-free extract, 3.5% fiber,
6.0% ash, and 10% water. The vitamin contents were
(IU/kg) 1500 vitamin D, 12,000 vitamin A, and (rest in
mg/kg) 63 vitamin E, 0.25 vitamin K1, 10 vitamin K3, 3
vitamin B1, 12 vitamin B2, 4 vitamin B6, 0.02 vitamin B12,
10 pantotenic acid, 1000 choline chloride, and 40 niacin.
The trace elements were (mg/kg) 30 copper, 190 iron,
100 manganese, 110 zinc, 2 iodine, and 1 cobalt. Surgery
was performed at 8 weeks of age; NTX was carried out
by removal of upper and lower poles of the left kidney,
and the whole right kidney [14, 15], while sham-operation
was performed by kidney decapsulation. Anesthesia, an-
tibiotics, postoperative pain relief, and measurement of
systolic blood pressure by tail-cuff were as previously re-
ported [14, 15].
In the 12-week study, 4 weeks after NTX (rat age 12
weeks), the animals were divided into four groups so that
systolic blood pressures and body weights in the sham
and calcium-sham, and NTX and calcium-NTX groups,
respectively (N = 9 to 10 in each) were similar. The sham
and NTX rats were switched to chow containing 0.3%
calcium, while calcium-sham and calcium-NTX rats con-
tinued on 3% calcium. Extra calcium was supplied as car-
bonate (AnalyCen).
In the 27-week study, 15 weeks after NTX (rat age
23 weeks), the rats were divided into two groups (NTX
and calcium-NTX) so that systolic blood pressures, body
weights, plasma creatinine (tail vein sampling at week 13),
and 24-hour urine volumes were similar (N = 13 to 14).
Eleven sham-operated rats served as controls. The sham
and NTX rats continued on 0.3%, and calcium-NTX rats
on 3% calcium (AnalyCen). These calcium diets were
chosen, since we have observed clear differences in cal-
cium metabolism after 0.3% versus 3.0% calcium intake
in rats, in the absence of adverse effects that would indi-
cate calcium deficiency or excess [14].
High calcium diets continued for 8 weeks (12-week
study) or 12 weeks (27-week study), and 24-hour fluid
consumption and urine output were measured during the
last study weeks. The rats were anaesthetized (urethane
1.3 g/kg), and blood samples from cannulated carotid
artery were drawn with ethylenediaminetetraacetic acid
(EDTA) and heparin as anticoagulants, as appropriate.
The hearts and the kidneys were removed and weighed.
In the 12-week study, a kidney half from four rats per
group, and in the 27-week study a kidney half and a
standard section of the thoracic aorta from all rats, were
fixed in 4% formaldehyde for 24 hours, and embedded in
paraffin. The remaining kidney pieces were snap-frozen
in isopentane at −40◦C and stored at −80◦C. The exper-
imental design of the study was approved by the Animal
Experimentation Committee of the University of Tam-
pere, and the Provincial Government of Western Finland
Department of Social Affairs and Health, Finland. The
investigation conforms to the Guiding Principles for Re-
search Involving Animals.
In vitro autoradiography of renal ACE and Ang II
receptors
Quantitative in vitro autoradiography of ACE and Ang
II receptors (AT1 and AT2) was performed on 20 lm
thick tissue sections with the radioligands [125I]-MK351A
and [125I]-Sar1, Ile8-Ang II, respectively, as described
earlier [16, 17]. The density of AT1 receptors was deter-
mined in the presence of the AT2 antagonist PD 123,313
(10 lmol/L), and the density of AT2 receptors in the pres-
ence of the AT1 antagonist losartan (10 lmol/L). The op-
tical densities were quantified by image analyzing system
(AIDA two-dimensional densitometry) coupled to the
FujiFilm BAS-5000 phosphoimager (Tamro, Finland).
Western blotting of renal ACE
Frozen tissues (100 mg) were lysed in 1 mL of sodium
dodecyl sulfate (SDS) buffer, pH 7.4, containing 10
mmol/L Tris-HCl, 2% SDS, and protein inhibitors
(CompleteTM Mini EDTA-free; Roche Diagnostics,
Mannheim, Germany). Debris was removed by cen-
trifugation (10,000g, 15 minutes), and protein concen-
trations were determined (Bio-Rad Laboratories, Inc.,
Richmond, CA, USA). Aliquots containing 50 lg of
protein in loading buffer (10% glycerol, 2% SDS,
Po¨rsti et al: Calcium intake and renal ACE 2157
60 mmol/L Tris-HCl, pH 6.8, 0.01% bromophenol blue,
and 100 mmol/L dithiothreitol) were boiled for 5 minutes
before electrophoresis on 12% SDS-polyacrylamide
gels. The proteins were electrophoretically transferred
to Immun-Blot polyvinylidene difluoride membrane
(Bio-Rad Laboratories, Inc.) in 25 mmol/L Tris-HCl,
pH 8.0, 192 mmol/L glycine, and 20% methanol at 50 V
overnight. After washing in H2O and Tris-buffered
saline with Tween (TBS-T) (20 mmol/L Tris-HCl, pH
7.6, 136 mmol/L NaCl, and 0.3% Tween-20), membranes
were blocked in 5% nonfat milk powder in TBS-T at
room temperature for 1 hour, and incubated for 3 hours
with goat polyclonal antibody against rat ACE (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA) diluted
1:200 in 5% milk in TBS-T buffer. After washing with
2.5% milk/TBS-T buffer, membranes were incubated
with 1:2000 dilution of horseradish peroxidase-
conjugated rabbit anti-goat IgG for 1 hour (Sigma-
Aldrich Co., St. Louis, MO, USA). Antibody binding was
detected by chemiluminescense (WB Chemiluminescent
Reagent Plus; NEN, Inc., Boston, MA, USA), and the
autoradiograph was analyzed with Image Gauge 3.3
software (Fuji Photo Film Co., Tokyo, Japan).
Kidney and aortic morphology, connective tissue growth
factor (CTGF) immunohistochemistry
Five micrometer-thick kidney sections were stained
with hematoxylin-eosin and periodic acid-Schiff (PAS),
von Kossa, or immonohistochemistry, and processed for
light microscopic evaluation. An expert who was blinded
to the treatments quantified all kidney tissue histology.
Glomerulosclerosis (hematoxylin-eosin and PAS stain).
A score for each animal was derived as the mean of 100
systematically examined glomeruli at a magnification of
×400: 0, normal; 1, mesangial expansion or thickening
of basement membrane; 2, segmental sclerosis involving
<50% of the tuft; 3, diffuse sclerosis involving >50% of
the tuft; and 4, diffuse glomerulosclerosis, total tuft oblit-
eration and collapse [18].
Tubulointerstitial damage (hematoxylin-eosin and PAS
stain). A scoring system was applied (from 0 to 4), in
which tubular atrophy, dilation, casts, interstitial inflam-
mation, and fibrosis were assessed in 10 kidney fields at
a magnification of ×100: 0, normal; 1, lesions in <25% of
the area; 2, lesions in 25% to 50% of the area; 3, lesions
in > 50% of the area; and 4, lesions involving the entire
area [18].
Calcification (von Kossa stain). Calcifications were
counted from 10 random kidney sections at ×200 magni-
fication. Each field was divided into 100 grids, and each
grid containing foci of calcification denoted one score.
Total scores of each field were counted. The index of cal-
cification was determined for each rat by the mean score
of the calculated 10 fields. Calcifications were also mea-
sured from aortic sections at ×200 magnification. The
total area of each aortic section, and area of calcifica-
tion, was measured by a computerized interactive system
(Scion Image Beta 4.02, Frederick, MD, USA). The index
of calcification for each rat was expressed as percentage
of the calcified area related to the total area of the aortic
cross-section.
Immunohistochemistry of CTGF. Five micrometer-
thick kidney samples were processed as described previ-
ously [19]. The samples were incubated in blocking serum,
and primary polyclonal antibody against mouse CTGF
that cross-reacts with rat CTGF (ab6992, 1:400) (Abcam,
Cambridge, UK) was applied for 60 minutes at room tem-
perature. Then the slides were incubated for 30 minutes
with biotinylated secondary antibody (antirabbit IgG;
Vector Laboratories, Burlingame, CA, USA), and for 30
minutes with peroxidase-labeled biotin-avidin-complex
using a commercial Elite ABC kit (Vector Laboratories).
The color reaction was developed by incubation for 15
minutes in a 3-amino-9-ethyl carbazole solution contain-
ing hydrogen peroxide. Finally, the sections were coun-
terstained with Mayer’s hemalum and mounted. Nega-
tive controls were treated with blocking serum with and
without nonspecific IgG instead of the primary antibody.
Positive CTGF label in tissue was scored from 0 to 3 using
light microscope [19].
PRA, electrolytes, phosphate, creatinine, urea
nitrogen, protein, hemoglobin, 1,25(OH)2D3, PTH,
creatinine clearance, and urine albumin
PRA was determined by radioimmunoassay (Ang I
RIA Kit; Diasorin S.p.a., Saluggia, Italy) according to
the manufacturer’s instructions. Urine albumin was de-
termined by nephelometry (Behring Nephelometer 100
analyzer; Behringwerke, Marburg, Germany) using rab-
bit antirat albumin antibodies (Cappel Cochranville,
Philadelphia, PA, USA) as reported earlier [20]. All other
determinations were carried out as previously described
in detail [14, 15].
Data presentation and analysis of results
The amounts of ACE and AT1 receptors in renal tissue
were depicted in relation to the mean value of the sham
group. Statistics were by one-way and two-way analyses
of variance (ANOVA), and the least significant differ-
ence test was used for post hoc analyses (SPSS 9.0, SPSS,
Inc., Chicago, IL, USA). If the distribution of the vari-
ables was skewed, the Kruskal-Wallis test was applied,
and post hoc analyses were performed with the Mann-
Whitney U test, the P values being corrected with the
Bonferroni equation. Spearman’s two-tailed correlation
coefficient (r) was used in the correlation analyses and the
Kaplan-Meier method in the survival analyses, in which
the difference between survivals was assessed using the
2158 Po¨rsti et al: Calcium intake and renal ACE
Table 1. The 12-week study: Experimental group data; 0.3% or 3.0% calcium diet during weeks 4 to 12
Sham Calcium-sham NTX Calcium-NTX
Body weight g 465 ± 7 465 ± 13 462 ± 7 459 ± 6
Heart weight/body weight g/kg 3.37 ± 0.06 3.33 ± 0.05 3.51 ± 0.10 3.52 ± 0.14
Renal tissue weight g 3.07 ± 0.08 2.83 ± 0.11 2.18 ± 0.13a 1.90 ± 0.09a
Renal tissue weight/body weight g/kg 6.56 ± 0.13 6.15 ± 0.22 4.67 ± 0.23a 4.18 ± 0.22a
Fluid intake mL 24.2 ± 3.3 28.2 ± 3.5 49.2 ± 6.3a 50.1 ± 4.8a
Urine volume mL 17.0 ± 1.8 21.4 ± 3.4 38.7 ± 2.9a 39.2 ± 4.1a
Systolic blood pressure mm Hg
Week 4 133 ± 4 132 ± 5 140 ± 4 138 ± 4
Week 12 138 ± 4 135 ± 4 154 ± 4a,b 148 ± 4b
Values are mean ± SEM (N = 9 to 10).
aP < 0.05 versus sham; bP < 0.05 NTX groups versus sham groups (150 ± 3 mm Hg versus 136 ± 3 mm Hg, two-way ANOVA).
Table 2. The 12-week study: Laboratory findings and proportions of angiotensin II (Ang II) type 2 (AT2) receptors; 0.3% or 3.0% calcium diet
during weeks 4 to 12
Sham Calcium-sham NTX Calcium-NTX
Plasma
Renin activity ng/mL/hour Ang I 42.9 ± 4.2 45.9 ± 1.1 16.8 ± 6.2a 21.7 ± 4.2a
Urea nitrogen mmol/L 6.01 ± 0.23 6.65 ± 0.25 9.94 ± 0.41a 11.06 ± 0.97a
Creatinine lmol/L 63.8 ± 2.1 66.9 ± 2.2 100.7 ± 2.9a 95.9 ± 5.4a
Ionized calcium mmol/L 1.35 ± 0.02 1.47 ± 0.02a 1.27 ± 0.01a 1.47 ± 0.02a,b
Phosphate mmol/L 1.44 ± 0.05 1.07 ± 0.07a 1.75 ± 0.10a 1.01 ± 0.10a,b
Ca x Pi product 2.03 ± 0.07 1.58 ± 0.10a 2.19 ± 0.12 1.55 ± 0.14a,b
Parathyroid hormone pg/mL 146.2 ± 22.0 39.8 ± 2.1 554.3 ± 79.7a 48.2 ± 5.4a,b
1,25(OH)2D3 pmol/L 91.6 ± 8.6 95.0 ± 4.9 74.9 ± 5.6c 81.1 ± 8.8c
Hemoglobin g/L 187.5 ± 3.2 182.1 ± 2.8 163.8 ± 5.4a 168.7 ± 1.8a
Sodium mmol/L 138.5 ± 0.4 137.5 ± 0.4 138.8 ± 0.5 138.5 ± 0.5
Potassium mmol/L 3.95 ± 0.12 3.65 ± 0.15 3.81 ± 0.12 4.10 ± 0.25
pH 7.46 ± 0.02 7.44 ± 0.02 7.45 ± 0.02 7.46 ± 0.02
Urine calcium lmol/24 hours 11.7 ± 2.1 398.9 ± 41.0a 40.6 ± 7.5a 452.7 ± 40.0a,b
Creatinine clearance lL/min/100 g body weight 296.0 ± 8.3 289.6 ± 7.2 244.7 ± 7.0a 261.8 ± 14.6a
Proportion of Ang II receptors %
AT2 receptors in renal cortex 0.65 ± 0.24 2.23 ± 1.15 1.45 ± 0.43 2.01 ± 0.59
AT2 receptors in renal medulla 0.93 ± 0.26 0.97 ± 0.19 1.45 ± 0.43 1.36 ± 0.37
Values are mean ± SEM (N = 9 to 10 for all groups).
aP < 0.05 compared with the sham group; bP < 0.05 compared with the NTX group; cP < 0.05 NTX groups versus sham groups (78.0 ± 5.0 pmol/L versus 93.3 ±
5.1 pmol/L, two-way ANOVA).
log rank test. Results were expressed as mean±SEM, and
differences were considered significant when P < 0.05.
RESULTS
Animal data in the 12-week study
No differences in body weights or heart weights were
detected between the groups, while renal mass in both
NTX groups was about 30% lower than in the sham group
(Table 1). Fluid intake and urine output were higher in
the NTX and calcium-NTX groups when compared with
sham rats. Systolic blood pressure was modestly elevated
12 weeks after NTX, and was not affected by increased
calcium intake (Table 1).
Laboratory findings in the 12-week study
PRA was clearly lower in both NTX groups than in
the sham-operated controls, and was not affected by
increased calcium ingestion. Plasma concentrations of
urea nitrogen and creatinine were 1.6-fold higher in the
NTX group when compared with sham, while no dif-
ferences between the NTX and calcium-NTX groups
were observed in these variables (Table 2). Plasma phos-
phate, calcium x phosphorus (Ca x Pi) product, and
PTH were increased, while ionized Ca2+, proteins and
hemoglobin were decreased in the NTX group when com-
pared with sham. High calcium diet elevated plasma ion-
ized calcium, and suppressed plasma phosphate, Ca x Pi
product, and PTH levels, in both NTX and sham rats.
Although plasma levels of active vitamin D in individual
study groups did not differ (NTX group vs. sham group,
P = 0.056), analyses by two-way ANOVA showed that
plasma 1,25(OH)2D3 was lower in the two NTX groups
than the sham groups (78.0 ± 5.0 pmol/mL versus 93.3 ±
5.1 pmol/mL, respectively, P = 0.043). The NTX group
showed a modest elevation in urinary calcium excretion,
while both groups on high calcium diet showed a marked
increase in calcium excretion. Creatinine clearance was
reduced in the NTX rats (Table 2).
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Table 3. The 27-week study: Experimental group data; 0.3% or 3.0%
calcium diet during weeks 15 to 27
Calcium-
Sham NTX NTX
Body weight g
Week 15 499 ± 8 475 ± 9 479 ± 9
Week 27 557 ± 7 498 ± 38a 488 ± 13a
Heart weight/body
weight g/kg
3.21 ± 0.03 4.19 ± 0.43a 4.03 ± 0.13a
Renal tissue weight g 3.34 ± 0.08 2.94 ± 0.34 2.37 ± 0.09a,b
Renal tissue
weight/body weight
g/kg
5.94 ± 0.09 5.93 ± 0.61 4.92 ± 0.16a
Fluid intake mL 27.7 ± 1.6 55.7 ± 5.4a 57.9 ± 4.9a
Urine volume mL 20.3 ± 1.4 40.7 ± 3.3a 43.6 ± 4.3a
Systolic blood pressure mm Hg
Week 15 133 ± 3 151 ± 5a 152 ± 4a
Week 27 129 ± 2 173 ± 4a 145 ± 3a,b
Rat number
Week 15 11 14 13
Week 27 11 7a 12b
Renal histology
Glomerulosclerosis
index
0.50 ± 0.04 1.91 ± 0.12a 1.39 ± 0.12a,b
Interstitial damage
index
0.54 ± 0.05 2.93 ± 0.28a 1.92 ± 0.09a,b
Calcification index 0 ± 0 99.3 ± 65.6a 3.6 ± 3.6b
Aortic calcification %
of cross-section
0 ± 0 5.8 ± 2.3a 0 ± 0b
Values are mean ± SEM (N = 7 to 14).
aP < 0.05 versus sham; bP < 0.05 versus NTX.
Animal data in the 27-week study
There were no differences in body weights at week 15,
but body weights were lower in both NTX groups when
compared with sham at week 27 (Table 3). The heart/body
weight ratio was higher in the NTX and calcium-NTX
groups when compared with sham. In the NTX group
the kidneys appeared macroscopically swollen whereby
the renal tissue/body weight ratio was similar to sham,
while the calcium-NTX group showed lower renal tis-
sue weights. Fluid intake and urine output were higher
in both NTX groups than in sham rats. Corresponding
to the 12-week experiment, both NTX groups exhibited
mild elevation of systolic blood pressure at study week 15.
During the follow-up period blood pressure increased in
the NTX group, whereas the high calcium diet showed a
significant antihypertensive effect (Table 3). At the end
of the study, only 7 of the initial 14 rats survived in the
NTX group, while survival was significantly improved in
the calcium-NTX group (Table 3) (Fig. 2A).
Laboratory findings in the 27-week study
Plasma concentration of creatinine was similarly ele-
vated in the NTX groups before the dietary interven-
tions at study week 13 (Table 4). At week 27, plasma
creatinine and urea nitrogen were further increased in
Table 4. The 27-week study: Laboratory findings and proportions of
angiotensin II (Ang II) type 2 (AT2) receptors; 0.3% or 3.0% calcium
diet during weeks 15 to 27
Calcium-
Sham NTX NTX
Plasma
Creatinine at
week 13 lmol/L
62.7 ± 1.6 90.1 ± 3.5a 91.0 ± 3.7a
Creatinine at
week 27 lmol/L
64.6 ± 2.0 186.0 ± 34.2a 118.0 ± 6.7a,b
Urea nitrogen
mmol/L
5.2 ± 0.2 23.7 ± 7.6a 12.8 ± 1.0a,b
Ionized calcium
mmol/L
1.36 ± 0.06 1.34 ± 0.03 1.55 ± 0.03a,b
Phosphate
mmol/L
1.16 ± 0.06 2.52 ± 0.46a 0.81 ± 0.08a,b
Ca x Pi product 1.55 ± 0.07 3.48 ± 0.59a 1.18 ± 0.11a,b
Parathyroid
hormone
pg/mL
88.3 ± 12.5 1171.0 ± 320.2a 3.7 ± 0.4a,b
Proteins g/L 64.3 ± 0.7 59.5 ± 1.2a 62.1 ± 0.5a,b
Hemoglobin g/L 174.8 ± 1.9 148.3 ± 10.7a 154.6 ± 1.8a
Sodium mmol/L 137.9 ± 0.6 138.6 ± 1.4 136.5 ± 0.4
Potassium
mmol/L
3.52 ± 0.11 4.52 ± 0.57a 3.56 ± 0.06b
pH 7.41 ± 0.02 7.28 ± 0.06a 7.40 ± 0.02b
Urine calcium
lmol/24 hours
22.2 ± 5.5 64.7 ± 8.6a 525.3 ± 37.4a,b
Creatinine clearance
lL/ min/100 g
body weight
353.4 ± 15.9 143.5 ± 24.7a 187.2 ± 10.9a
Proportion of Ang II receptors%
AT2 receptors in
renal cortex
0.26 ± 0.17 0.32 ± 0.28 0.22 ± 0.11
AT2 receptors in
renal medulla
0.34 ± 0.18 0.16 ± 0.11 0.12 ± 0.09
Values are mean ± SEM (N = 7 to 14 for all groups).
aP < 0.05 versus sham; bP < 0.05 versus NTX.
the NTX group, while both of these values were lower
in the calcium-NTX than the NTX group. Plasma phos-
phate, Ca x Pi product, and PTH were increased in the
NTX group, while all of these values were lower in the
calcium-NTX than the sham group. Plasma-ionized cal-
cium did not differ from sham in the NTX group, but was
increased in calcium-NTX rats (Table 4).
Hemoglobin and plasma proteins were lower in both
NTX groups than in sham rats, while proteins were higher
in the calcium-NTX than the NTX group. Plasma pH was
decreased and potassium increased in the NTX group,
whereas these variables in the calcium-NTX group were
not different from sham. Daily urinary calcium excretion
was moderately increased in the NTX group, whereas
calcium-NTX rats showed a marked increase in urinary
calcium. Creatinine clearance was lower in the NTX
groups when compared with the sham group (Table 4).
Renal and aortic histology
In the 12-week study, the indices of glomerulosclerosis
and interstitial damage (arbitrary scale from 0 to 4), and
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number of calcifications (deposits/cm2) in kidney tissue,
were higher in the NTX group than the calcium-NTX
group (0.70 ± 0.11 versus 0.11 ± 0.01, 1.30 ± 0.18 versus
0.38 ± 0.03, and 12.5 ± 3.0 versus 2.0 ± 1.3, respectively,
P < 0.05 for all comparisons). No differences in tissue
histology were detected between the sham and calcium-
sham groups (not shown).
In the 27-week study the indices of glomeruloscle-
rosis, tubulointerstitial damage, and kidney tissue cal-
cification were clearly increased in the NTX group
(Table 3). All of these indices were lower in the calcium-
NTX than the NTX group. High calcium diet also sig-
nificantly reduced calcifications in the thoracic aorta
(Table 3).
Renal components of RAS and albumin excretion in the
12-week study
When analyzed using quantitative in vitro autoradiog-
raphy, which measures binding to the active site of ACE
[21], the renal tissue ACE content was approximately
40% lower in the calcium-sham and calcium-NTX groups
when compared with the sham and NTX groups (Fig. 1A
and B). The distribution of ACE was also different be-
tween NTX and sham rats (Fig. 1A). The highest ACE
signal was detected in a circular fashion in the inner cor-
tex and outer medulla in the sham group, whereas ACE
was more widely distributed throughout the remnant kid-
ney in the NTX group. The outcome of ACE protein de-
termination by Western blotting well paralleled the re-
sults of autoradiography: renal ACE was lower in the
calcium-NTX group when compared with the NTX and
sham groups (Fig. 1C). ACE did not differ between NTX
and sham groups (Fig. 1A to C).
AT1 receptor density in kidney cortex was slightly re-
duced in the NTX and calcium-sham groups when com-
pared with the sham group, while no significant differ-
ences in cortical AT1 receptor density were detected be-
tween the NTX and calcium-NTX groups (Fig. 1E). AT1
density in renal medulla (Fig. 1F), and AT2 density in
cortex and medulla (not shown), was similar in all study
groups. The average proportion of AT2 of all Ang II re-
ceptors in the kidney varied 0.65% to 2.23%, with no
significant differences between the groups (Table 2).
The scatter plots depicting the variables of calcium
metabolism in relation to renal tissue ACE, determined
by autoradiography, showed clustering of data points in
separate subgroups in the NTX and calcium-NTX groups
(Fig. 2A to D). In the NTX groups, renal tissue ACE con-
tent correlated to urinary albumin excretion (r = 0.512,
P = 0.025), and inversely correlated to cortical AT2 re-
ceptor density (r = −0.574, P = 0.010). Both of these
correlations were significant if the NTX group alone was
included in the analyses (r = 0.733, P = 0.025 and r =
−0.705, P = 0.034, respectively).
The level of daily urinary albumin excretion was in-
creased in NTX rats, but was lower in the calcium-NTX
than the NTX group (Fig. 1D).
Renal components of RAS and CTGF in the 27-week
study
Measurements using autoradiography in vitro showed
that kidney tissue ACE content was lower in the calcium-
NTX group when compared with the sham and NTX
groups (Fig. 3C). The outcome of Western blotting con-
firmed that renal ACE protein was significantly reduced
in the calcium-NTX group when compared with the NTX
group, while ACE protein was increased in the NTX
group when compared with sham (Fig. 3D).
AT1 density in renal cortex (autoradiography) was
lower in the calcium-NTX than the NTX group (Fig. 2E).
No differences in renal cortical AT1 density between the
NTX and sham groups, and renal medullary AT1 den-
sity between any of the study groups, were observed (Fig.
2F). The proportion of cortical and medullary AT2 was
less than 0.34% of all Ang II receptors, with no significant
differences between the study groups (Table 4).
Since CTGF has been suggested to be a mediator of
Ang II–induced tissue damage [22, 23], we measured re-
nal CTGF content in the study groups using immunohis-
tochemistry. Kidney CTGF score was markedly increased
in the NTX group when compared with sham, whereas
the CTGF score was significantly lower in the calcium-
NTX than the NTX group (Fig. 3B).
DISCUSSION
The present study for the first time demonstrated that
high calcium diet reduces kidney ACE content in rats
with CRF, with an associated decrease in albuminuria and
beneficial influence on kidney morphology. Two methods
were applied to assess renal ACE: autoradiography that
measures binding to the active site of ACE, and West-
ern blotting that measures ACE protein. Previously, a
linear relationship between radioligand binding to ACE
in tissue sections, as determined by quantitative in vitro
autoradiography, and ACE activity in tissue membrane
suspensions, as measured by enzymatic assay, has been
reported [21]. Here we examined the effects of calcium
supplementation on renal ACE and Ang II receptors, be-
cause high calcium diet has reduced blood pressure [4],
enhanced vasorelaxation [5], increased sodium excretion
[9], and decreased PRA in experimental hypertension [6].
Such effects of increased calcium intake resemble those
that are achieved by inhibition of the actions of RAS. Fur-
thermore, infusion of the N-terminal 34 amino acid PTH
peptide increases renin release in dogs [24], whereas in-
creased calcium intake results in suppression of plasma
PTH levels [3]. An inverse relationship between the levels
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of calcium-regulating hormones and activity of circulat-
ing RAS has also been reported in essential hypertension
[25, 26].
In this study, renal failure was induced by surgical 5/6
renal ablation, and the NTX rats showed several charac-
teristic findings of CRF (Tables 1 to 4), which well cor-
respond to previously published results [15, 27]. Blood
pressure was modestly elevated 12 weeks after NTX, and
further increased during the 27-week follow-up. Corre-
sponding to the reports in experimental hypertension [15,
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−→
Fig. 3. The 27-week study. Cumulative survival (A), immunohistochemistry of kidney tissue connective tissue growth factor (CTGF) (B), renal
tissue angiotensin-converting enzyme (ACE) determined by autoradiography (C) and Western blotting (D), and angiotensin II type 1 (AT1) receptor
density in renal cortex (E) and medulla (F); quantities of ACE and AT1 receptors were related to the mean value of the sham group. Mean ± SEM
(N = 7 to 11 in each group). ∗P < 0.05 versus sham; †P < 0.05 versus NTX.
27], the high calcium diet showed a clear antihyperten-
sive effect in the 27-week study. The finding that Sprague-
Dawley rats do not readily develop overt hypertension af-
ter surgical 5/6 renal mass reduction has been attributed
to low activity of circulating RAS in this model [27]. This
view is supported by the present results, since PRA was
clearly lower in the NTX rats than in sham rats.
Secondary hyperparathyroidism is a common compli-
cation of CRF, and the causes for increased PTH secretion
are high plasma phosphate, low ionized calcium, and low
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calcitriol [3]. Successful treatment of high phosphate can
ameliorate the progression of secondary hyperparathy-
roidism and reduce cardiovascular complications in CRF
[2, 3]. High phosphate and PTH levels increase the risk
of ectopic calcifications [3], and elevated phosphate may
directly induce phenotypic changes in vascular smooth
muscle that predispose the vessel wall to calcification
[28]. Because of increased ingestion of calcium salts to
control phosphate and PTH, renal patients are subjected
to a substantial calcium burden, which may predispose
to the accumulation of calcium salts in extraskeletal tis-
sues [3]. However, in experimental CRF increased intake
of calcium carbonate has actually reduced kidney calci-
fication, the probable mechanism being the lowering of
plasma phosphate [29].
In the present study, we found that plasma phosphate
and PTH were effectively reduced by the high calcium
diet. The elevated ionized calcium levels and suppressed
PTH levels indicate that increased calcium intake actu-
ally resulted in mild hypercalcemia in the 27-week study.
In spite of this, the increase in renal and aortic tissue cal-
cifications was prevented by elevated calcium ingestion
in NTX rats (Table 3), probably because of the effective
suppression of plasma phosphate and Ca x Pi product.
The reduced mortality in the NTX rats ingesting the high
calcium diet (Fig. 3A) argues against the view that in-
creased calcium intake would be toxic to the animals in
this model of CRF. Furthermore, since the samples of
severely affected rats in the 27-week study were lost due
to the reduced survival in the NTX group, the present
evaluation probably underestimated the extent of tissue
damage and decline of renal function in this group. Al-
together the present results suggest that especially hy-
perphosphatemia, but not mild hypercalcemia alone, is
detrimental to the kidneys and vasculature in CRF.
A decrease in renal calcification with a high calcium
diet seems to contradict with the opinion that such a diet
may be deleterious to patients with advanced CRF. This
view is based on clinical reports, which showed an as-
sociation between soft tissue calcifications and high oral
calcium supplements in hemodialysis patients [30, 31].
Most studies have reported that high concurrent circu-
lating levels of phosphorus and calcium, or high Ca x Pi
product, are risk factors for calcification, but have not
given detailed information about dietary calcium intake
in these patients [32, 33]. Thus, calcium-based phosphate
binders may be associated with progressive vascular cal-
cification if hyperphosphatemia is not adequately con-
trolled [31]. However, all clinical reports have not shown
that increased oral calcium load would be a risk factor for
soft tissue calcification in dialysis patients [34]. A recent
analysis stressed the importance of examining combina-
tions of parameters of calcium-phosphorus metabolism,
and not single variables alone, when assessing cardiovas-
cular risk in hemodialysis patients [35]. A thorough anal-
ysis of dietary calcium intake, with reliable information
about patient compliance, should be included in such an
approach.
The NTX group showed higher albumin excretion (12-
week study) and increased indices of glomerulosclerosis
and interstitial damage (12-week and 27-week studies),
while high calcium intake was associated beneficial in-
fluence on albuminuria and kidney morphology. These
findings may be due to the observed changes in cal-
cium metabolism. Another putative explanation would
be down-regulation of components of RAS in the kidney,
since renal tissue ACE content was significantly reduced
after increased calcium ingestion in NTX rats. In the 12-
week study, no differences in renal AT1 density were ob-
served between the NTX and calcium-NTX groups, but a
significant decrease in cortical AT1 density was detected
in the calcium-supplemented sham-operated rats. In the
27-week study, high calcium intake reduced cortical AT1
receptor density in NTX rats. Subsequently, the net effect
of lower ACE without changes, or a concurrent decrease,
in cortical AT1 receptor density, could result in reduced
Ang II action at the tissue level, and provide an expla-
nation to the observed beneficial results on morphology
and albumin excretion.
Local intrarenal RAS is an important determinant of
tissue injury, inflammation, and progression of renal dis-
ease, while inhibition of RAS can preserve renal function
in kidney diseases [13, 27, 36]. After subtotal nephrec-
tomy, pathologic expression of renin and Ang II has been
reported in rat kidneys [36]. In the 27-week study we
found that renal tissue ACE was increased in the NTX
group when determined by Western blotting, while only
an insignificant trend was observed using autoradiogra-
phy. This discrepancy can be explained by the patchy
and wider distribution of ACE in the remnant versus
sham-operated kidneys (Fig. 1A), which somewhat in-
terferes with the autoradiography analysis when compar-
ing normal and remnant kidney tissue. However, reliable
comparisons between the NTX and calcium-NTX groups
could be performed, as evidenced by the parallel out-
comes of the autoradiographs and Western blotting in
these rats.
Previously, Ang II has been reported to up-regulate
several proinflammatory mediators in the kidney [13].
Especially the prosclerotic cytokine CTGF has been sug-
gested as a mediator of the Ang II–induced fibrosis and
tissue damage [22, 23]. Therefore, we measured CTGF
content in the kidney by the use of immunohistochem-
istry. The results showed that CTGF score was markedly
increased in the NTX group, whereas the score was sig-
nificantly lower in the calcium-NTX than the NTX group
(Fig. 3B). This finding supports the view that Ang II ac-
tion at the tissue level was reduced by the high calcium
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diet. In experimental CRF, disturbed calcium balance and
hyperphosphatemia have been previously linked with in-
creased tissue fibrosis and thickening of arterial wall [37],
the findings of which resemble the structural changes that
are associated with long-term activation of RAS at the
tissue level [13, 36].
The regulation of ACE in tissues is not well under-
stood. In the kidney intense proteinuria up-regulates
ACE [38], while in cultured endothelial cells ACE
expression is induced by vascular endothelial growth
factor [39] and down-regulated by tumor necrosis
factor-a [40]. The present results showed that alterations
in calcium-phosphate balance contribute to the regula-
tion of ACE in the kidney. In addition to its other phys-
iologic roles, extracellular calcium ion functions like a
hormone by regulating cellular processes through spe-
cific calcium receptor–mediated mechanisms [10]. In
the nephron, high calcium delivery stimulates calcium-
sensing receptors, the mechanism of which plays a role in
the enhanced natriuresis induced by high calcium inges-
tion [10]. In vascular tissue, elevated extracellular cal-
cium concentration can increase the synthesis of pro-
teins that inhibit soft tissue calcification, via a mecha-
nism that is functionally related to the calcium-sensing
receptor [41]. Some of the proteins that regulate calcifi-
cation belong to the transforming growth factor-b family
of cytokines [42]. Whether high renal calcium delivery
influences the synthesis of calcification-regulation pro-
teins, and whether these proteins in turn influence the
expression of renal components of RAS, remain to be
studied in the future. Interestingly, AT2 receptor ac-
tivation has been reported to decrease ACE activity,
which may partially underlie AT2’s attenuation of AT1-
mediated actions [43]. Our findings suggested an inverse
correlation between renal ACE and AT2 receptors, thus
supporting a link between the regulations of these two
components of RAS in kidney tissue. It is also noteworthy
that increased calcium intake down-regulated renal ACE
without a compensatory increase in circulating PRA.
In addition to the changes in calcium-phosphate bal-
ance, a multitude of mechanisms could explain the effects
of high calcium diet on renal tissue ACE. As the dietary
intake of calcium changes, so do levels of calcitonin, cal-
citonin gene-related peptide, natriuretic peptides, sym-
pathetic nervous system activity, metabolism of other
electrolytes, calcium-binding proteins, intracellular free
calcium levels, membrane-bound calcium, and cellular
electrolyte fluxes [4]. Any of these changes, or their com-
bination, could be the source of altered ACE, and the
precise molecular mechanism of the down-regulation of
renal ACE expression by increased calcium intake is
a subject for further studies. In concert with the view
that calcium supplementation can modulate gene ex-
pression in the kidney, increased dietary calcium intake
was recently found to normalize the disturbances in cal-
cium homeostasis in mice in which the 25OH D3-1a-
hydroxylase gene was inactivated [11]. In these mice high
calcium diet was shown to regulate the expression of renal
calcium transport protein genes, but also the expression
of a large number of other genes that were not previously
identified as playing a role in renal calcium handling [11].
CONCLUSION
Our results showed that high calcium diet not only
suppressed plasma phosphate and PTH, and increased
plasma ionized calcium, but also reduced albuminuria,
favorably influenced kidney morphology, and down-
regulated kidney ACE in experimental renal fail-
ure. These findings suggest a link between calcium
metabolism and ACE expression in kidney tissue that
could also be important in the progression of renal dam-
age.
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